Necrobiotic Xanthogranuloma
Necrobiotic xanthogranuloma (NXG) is a very rare, chronic, progressive non-Langerhans cell histiocytosis that can be clinically serious. It produces firm yellow-orange to red-violet papules, nodules or ridged plaques that tend to develop central necrosis, ulceration and atrophy. The area around the eyes (the periorbital region) is the favored site, involved in up to 85% of cases.
NXG is far more than a cosmetic skin problem: it is regarded as a cutaneous marker of malignant bone marrow disease. Over 80% of patients have a monoclonal gammopathy, most often IgG kappa or IgG lambda, and they are at very high risk of already having or later developing multiple myeloma (Kahler disease), lymphoma or other lymphoproliferative or histiocytic disorders.
Exactly how NXG causes collagen necrosis and lipid deposition is still under study. The leading theory is that monoclonal proteins (paraproteins) bind plasma lipoproteins to form immune complexes that settle in the dermis. Macrophages then engulf the lipid, becoming foam cells and Touton giant cells, and release tissue-digesting enzymes that cause coagulative necrosis (necrobiosis).
At Haute-Derma, we treat periorbital NXG with a high level of suspicion. Patients face not only facial disfigurement and serious eye damage that can lead to blindness, but also the possibility of an underlying blood cancer.
Clinical Features, Eye Involvement and Systemic Disease
- Characteristic Skin Lesions:
- Typical sites: around the eyes (upper and lower lids, bridge of the nose, temples). Lesions can also appear on the trunk, forearms and lower legs.
- How lesions evolve: they begin as pale yellow, pink or violet-rimmed red papules or deep nodules. Over time these merge into large, firm plaques with a thin, atrophic surface and prominent telangiectasia. They readily break down into deep ulcers covered by gray-brown crust and heal with disfiguring atrophic scars.
- Symptoms: usually painless or mildly tender, with persistent itching and burning once ulceration sets in.
- Serious Eye Complications (in 50–60% of patients): deep histiocytic infiltration can cause scleritis, episcleritis, ulcerative keratitis, uveitis and ectropion, and can end in complete blindness.
- Systemic Involvement and Hematologic Malignancy:
- Monoclonal gammopathy / multiple myeloma: the most common association. The monoclonal protein may be present when the skin lesions appear or may only emerge years later.
- Histiocytic infiltration of internal organs: the heart (myocarditis, histiocytic vascular occlusion), liver, spleen, lungs, ovaries and central nervous system.
Diagnosis and Clinical Management at Haute-Derma
For patients with ulcerating xanthomatous lesions around the eyes, Haute-Derma follows a rigorous pathway of tissue diagnosis and hematologic screening:
Dermoscopy and Diagnostic Skin Biopsy
- Digital dermoscopy: shows a yellow-orange to brick-red background crossed by a dense network of arborizing vessels, a violaceous infiltrated border, and necrotic ulcers with crust.
- Skin biopsy and histopathology (the gold standard):
- A granulomatous infiltrate through the full thickness of the dermis, extending into the subcutaneous fat.
- Broad bands of collagen necrosis (large areas of necrobiosis).
- Abundant Touton giant cells and foreign body giant cells and, in particular, cholesterol clefts inside or outside the cells.
- Lymphoid follicles with germinal centers at the edge of the lesion.
Cosmetic Procedures Are Strictly Contraindicated
- No CO2 laser, chemical peels, sclerotherapy or dermabrasion: CO2 laser, Q-switched laser, chemical peels and purely cosmetic excision must never be used on NXG lesions. Mechanical or invasive procedures on NXG-affected skin cause extensive non-healing ulcers, severe secondary infection and a strong Koebner response.
- Supportive care and eye protection: wounds are cleansed with a hypochlorous acid (HOCl) solution and treated with a barrier-repair moisturizer using a 3:1:1 lipid ratio, and patients are referred to ophthalmology for eye drops to protect the conjunctiva and cornea.
Urgent Hematologic and Myeloma Screening
Every patient with biopsy-confirmed NXG must be referred urgently to hematology/oncology for the following tests:
- Serum (SPEP) and urine (UPEP) protein electrophoresis: to look for a monoclonal band (M-protein/paraprotein).
- Serum free light chain assay (kappa/lambda ratio).
- Bone marrow aspirate and biopsy: measures the proportion of plasma cells to confirm multiple myeloma or MGUS (monoclonal gammopathy of undetermined significance).
- Systemic treatment (directed by the hematologist): myeloma regimens may include high-dose corticosteroids, alkylating agents (melphalan, cyclophosphamide), proteasome inhibitors (bortezomib), immunomodulatory drugs (thalidomide, lenalidomide), or surgery/radiotherapy when there is compression of nearby structures.
